OSI Systems, NVE, Clene, Biodexa Pharmaceuticals, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies whose core business involves researching, developing or manufacturing materials, devices and processes at the nanometer scale. They give investors exposure to innovations like nanosensors, nanoelectronics and nanomedicine, which promise advances across industries from healthcare to energy. Because the field is still emerging and highly technical, these equities can be volatile but may offer significant long-term growth potential as breakthroughs take hold. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
Shares of OSIS traded down $2.20 during trading hours on Friday, reaching $217.99. The stock had a trading volume of 215,941 shares, compared to its average volume of 195,206. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56. OSI Systems has a 52 week low of $129.18 and a 52 week high of $234.59. The firm has a 50-day moving average of $206.39 and a 200 day moving average of $191.11. The company has a market cap of $3.66 billion, a P/E ratio of 28.06, a P/E/G ratio of 1.81 and a beta of 1.28.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
Shares of NVEC traded down $0.51 during trading hours on Friday, reaching $72.57. The stock had a trading volume of 224,528 shares, compared to its average volume of 23,824. NVE has a 52 week low of $51.50 and a 52 week high of $89.98. The firm has a 50-day moving average of $63.40 and a 200 day moving average of $70.91. The company has a market cap of $351.02 million, a P/E ratio of 23.41 and a beta of 1.09.
Read Our Latest Research Report on NVEC
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Shares of CLNN traded up $0.38 during trading hours on Friday, reaching $3.12. The stock had a trading volume of 189,676 shares, compared to its average volume of 82,185. Clene has a 52 week low of $2.28 and a 52 week high of $9.20. The firm has a 50-day moving average of $2.85 and a 200 day moving average of $4.00. The company has a market cap of $28.03 million, a P/E ratio of -0.59 and a beta of 0.46.
Read Our Latest Research Report on CLNN
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Shares of BDRX traded up $0.02 during trading hours on Friday, reaching $1.08. The stock had a trading volume of 404,338 shares, compared to its average volume of 844,338. Biodexa Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $41.50. The firm has a 50-day moving average of $1.39 and a 200 day moving average of $3.10.
Read Our Latest Research Report on BDRX
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Shares of VRPX traded up $0.01 during trading hours on Friday, reaching $0.25. The stock had a trading volume of 3,085 shares, compared to its average volume of 201,377. Virpax Pharmaceuticals has a 52 week low of $0.13 and a 52 week high of $84.75. The firm has a 50-day moving average of $0.39 and a 200 day moving average of $5.50.
Read Our Latest Research Report on VRPX
Recommended Stories
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
